Eyeworld CME Supplements

EW_FEB 2017_Supported by unrestricted educational grants from Alcon Laboratories Inc., Allergan Inc., Shire Pharmaceuticals, TearLab, and TearScience

This is a supplement to EyeWorld Magazine that doctors can take a test after reading and receive CME credits for.

Issue link: http://cmesupplements.eyeworld.org/i/777603

Contents of this Issue

Navigation

Page 0 of 7

365 Curriculum OSD: Honing diagnostic protocols to pinpoint disease, enhance surgical outcomes Supported by unrestricted educational grants from Alcon Laboratories Inc., Allergan Inc., Shire Pharmaceuticals, TearLab, and TearScience continued on page 2 Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Society of Cataract and Refractive Surgery (ASCRS) and EyeWorld. ASCRS is accredited by the ACCME to provide continuing medical education for physicians. Educational Objectives Ophthalmologists who participate in this activity will: • Identify the true impact of a dysfunc- tional ocular surface on cataract and refractive outcomes, identify the conse- quences that accompany an unstable tear film, and discuss the presentation of symptomatic vs. asymptomatic OSD • Describe the objective evidence supporting the use of new OSD diagnostic tools and develop strategies for incorporating new diagnostic tools into practice, including: inclusion in point-of-care and preoperative testing, use of diagnostic information to guide treatment, and utilization of diagnostics to follow success of interventions or treatment • Improve practice protocols for the screening, diagnosis, and classifica- tion of OSD and integrate consistent treatment regimens Designation Statement The American Society of Cataract and Refractive Surgery designates this enduring materials educational activity for a maximum of 1.0 AMA PRA Category 1 Credits. ™ Physicians should claim only credit commensurate with the extent of their participation in the activity. Claiming Credit To claim credit, participants must visit bit.ly/2j9eZpt to review content and download the post-activity test and credit claim. All participants must pass the post-activity test with a score of 75% or higher to earn credit. Alternatively, the post-test form included in this supplement may be faxed to the number indicated for credit to be awarded, and a certificate will be mailed within 2 weeks. When viewing online or downloading the material, standard internet access is required. Adobe Acrobat Reader is needed to view the materials. CME credit is valid through August 31, 2017. CME credit will not be awarded after that date. Notice of Off-Label Use Presentations This activity may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. ADA/Special Accommodations ASCRS and EyeWorld fully comply with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Any participant in this educational program who requires special accommodations or services should contact Laura Johnson at ljohnson@ascrs. org or 703-591-2220. Financial Interest Disclosures Jessica Ciralsky, MD, has received a retainer, ad hoc fees or other consulting income from Abbott Medical Optics, Allergan, Bausch + Lomb, and Shire. Preeya Gupta, MD, has received a retainer, ad hoc fees or other consulting income from: Abbott Medical Optics, Alcon Laboratories, Allergan, Bio-Tissue, NovaBay Pharmaceuticals, RPS, Shire, TearLab, and TearScience. Francis Mah, MD, has received a retainer, ad hoc fees, or other consulting income from Abbott Medical Optics, Aerie Phar- maceuticals, Alcon Laboratories, Allergan, Bausch + Lomb, CoDa, NovaBay, Ocular Science, Okogen, Omeros, PolyActiva, Shire, Sun Pharma, Sydnexis, and TearLab. He is a member of the speakers bureaus of Alcon, Allergan, Abbott Medical Optics, and Bausch + Lomb. Dr. Mah has received research funding from Abbott Medical Optics and Allergan. William Trattler, MD, has an investment interest in Alphaeon, ArcScan, and CXLO. He has received a retainer, ad hoc fees, or other consulting income from, and is a member of the speakers bureau of: Abbott Medical Optics, Allergan, Avedro, Bausch + Lomb, Shire, and Sun Pharma. He has received a retainer, ad hoc fees or other consulting income from Alcon Laborato- ries, and is a member of the speakers bu- reau of NovaBay. Dr. Trattler has received research funding from Allergan. Staff members: Kristen Covington and Laura Johnson have no ophthalmic-related financial interests. I n our quest to im- prove cataract surgery outcomes, we use the latest formulas, IOLs, and surgical technologies. To make the most of the newest innovations, we need accurate preoperative measurements, but dry eye can interfere with these readings. To help patients achieve the best refractive outcomes, surgeons need to enhance their dry eye assessment protocols to more accurate- ly diagnose dry eye before surgery. Dry eye impact Many patients who are eval- uated for cataract surgery do Undiagnosed dry eye can have far-reaching consequences in cataract patients by William Trattler, MD The ocular surface: A key factor in patient dissatisfaction William Trattler, MD " To make the most of the newest innovations, we need accurate preoperative measurements, but dry eye can interfere with these readings. " –William Trattler, MD not have significant symp- toms of dry eye. However, during an objective examina- tion, which includes corneal staining, tear break-up time, and other tests, patients may have findings of ocular surface disease (OSD), which can impact preoperative imaging and IOL power calculations. EyeWorld February 2017 Ocular surface disease (OSD) Click to read and claim CME credit

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld CME Supplements - EW_FEB 2017_Supported by unrestricted educational grants from Alcon Laboratories Inc., Allergan Inc., Shire Pharmaceuticals, TearLab, and TearScience